Market Research Logo

Colitis - Pipeline Review, H2 2015

Colitis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Colitis - Pipeline Review, H2 2015’, provides an overview of the Colitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Colitis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Colitis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Colitis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Colitis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Colitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Colitis Overview
Therapeutics Development
Pipeline Products for Colitis - Overview
Pipeline Products for Colitis - Comparative Analysis
Colitis - Therapeutics under Development by Companies
Colitis - Therapeutics under Investigation by Universities/Institutes
Colitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Colitis - Products under Development by Companies
Colitis - Products under Investigation by Universities/Institutes
Colitis - Companies Involved in Therapeutics Development
Aerpio Therapeutics, Inc.
Ajinomoto Pharmaceuticals Co., Ltd.
Akebia Therapeutics, Inc.
Amorepacific Corporation
Bayer AG
Dr. Falk Pharma GmbH
Galapagos NV
GeneFrontier Corporation
Innate Pharma SA
Nivalis Therapeutics, Inc.
Peptinov SAS
Prokarium Limited
Protalix BioTherapeutics, Inc.
RDD Pharma Ltd.
Saniona AB
Synovo GmbH
Colitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AcTMP-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AKB-4924 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AKB-6899 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AN-346 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antibodies to Inhibit Heparanase for Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antisense RNAi Oligonucleotides to Inhibit TNFalpha for Inflammatory Diseases and Colitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
APY-0201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BC-1215 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
budesonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
clostridium difficile vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CSY-0073 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Antagonize TRP Channel for Inflammatory Diseases and Colitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgotinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GFC-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IPH-33 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mesalamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N-6022 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N-6547 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NK-007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PAC-14028 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide to Inhibit NFkB for Colitis and Enteritis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PPV-06 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDD-2007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Inhibit TNF-Alpha for Crohn's Disease and Colitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Colitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptides to Inhibit Panx1 for Colitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine to Target Interleukin 12 and Interleukin 23 for Colitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine to Target Interleukin-23 for Colitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZK-216348 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Colitis - Recent Pipeline Updates
Colitis - Dormant Projects
Colitis - Discontinued Products
Colitis - Product Development Milestones
Featured News & Press Releases
Jul 11, 2013: Mylan Confirms First-to-File Patent Challenge Relating to CANASA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Colitis, H2 2015
Number of Products under Development for Colitis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Colitis - Pipeline by Aerpio Therapeutics, Inc., H2 2015
Colitis - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H2 2015
Colitis - Pipeline by Akebia Therapeutics, Inc., H2 2015
Colitis - Pipeline by Amorepacific Corporation, H2 2015
Colitis - Pipeline by Bayer AG, H2 2015
Colitis - Pipeline by Dr. Falk Pharma GmbH, H2 2015
Colitis - Pipeline by Galapagos NV, H2 2015
Colitis - Pipeline by GeneFrontier Corporation, H2 2015
Colitis - Pipeline by Innate Pharma SA, H2 2015
Colitis - Pipeline by Nivalis Therapeutics, Inc., H2 2015
Colitis - Pipeline by Peptinov SAS, H2 2015
Colitis - Pipeline by Prokarium Limited, H2 2015
Colitis - Pipeline by Protalix BioTherapeutics, Inc., H2 2015
Colitis - Pipeline by RDD Pharma Ltd., H2 2015
Colitis - Pipeline by Saniona AB, H2 2015
Colitis - Pipeline by Synovo GmbH, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Colitis Therapeutics - Recent Pipeline Updates, H2 2015
Colitis - Dormant Projects, H2 2015
Colitis - Dormant Projects (Contd..1), H2 2015
Colitis - Dormant Projects (Contd..2), H2 2015
Colitis - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Colitis, H2 2015
Number of Products under Development for Colitis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report